GSK reports positive interim results from Phase II AZUR-1 trial of Jemperli
GSK says interim results from the Phase II AZUR-1 study of Jemperli (dostarlimab) monotherapy were positive, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
British drugmaker GSK plc said interim results from the Phase II AZUR-1 trial, which evaluates Jemperli (dostarlimab) as monotherapy, were positive. The information was reported by Reuters based on the company's statement.
The original text does not disclose further trial details, so the news is informational in nature.
why it matters
For investors, interim data on a drug like this matters mainly as a signal about GSK's oncology pipeline; it rarely moves the shares of a large pharmaceutical company materially.
market impact
GSK: positive interim oncology data gives modest support to the company's shares
tags
instruments
sources
- GSK Says Positive Interim Results From Phase Ii Azur-1 Trial Evaluating Jemperli (Dostarlimab) Monotherapy — Reuters, 24 October 2026 at 22:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗